ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Early Rheumatoid Arthritis"

  • Abstract Number: 0812 • ACR Convergence 2021

    Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis

    Mary Lucy Marques1, Alessia Alunno2, Louise Falzon3, Annelies Boonen4 and Sofia Ramiro1, 1Leiden University Medical Center, Leiden, Netherlands, 2University of Perugia, Perugia, Italy, 3Center for Personalized Health, Northwell Health, New York City, NY, 4Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands

    Background/Purpose: Treatment of early RA with DMARDs is associated with particularly effective responses, resulting in sustained beneficial outcomes, including clinical and radiographic remission and optimal…
  • Abstract Number: L07 • 2019 ACR/ARP Annual Meeting

    A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis

    Liam O'Neil1, Victor Spicer 1, Irene Smolik 1, Xiaobo Meng 1, John Wilkins 1 and Hani El-Gabalawy 2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are currently the primary biomarker for identifying individuals at increased risk for future RA development. However, we have recently shown…
  • Abstract Number: 521 • 2019 ACR/ARP Annual Meeting

    Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis

    Zulema Rosales Rosado1, pia Lois 1, Arkaitz Mucientes Ruiz 1, Esperanza Pato Cour 1, Dalifer Freites Nuñez 2, Juan Angel Jover Jover 1, lydia Abasolo Alcazar 1 and Leticia León 3, 1HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, 2Hospital Clínico San Carlos, MADRID, Spain, 3Fundación para la Investigación Biomedica, Madrid, Madrid, Spain

    Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
  • Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting

    Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis

    Zoe Brown 1, Robert Metcalf 2, Jana Bednarz 3, Christiana Stavrou 4, Llewellyn Spargo 2, Michael James 2 and Susanna Proudman5, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, 3Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, 4University College London Hospital, London, United Kingdom, 5University of Adelaide, Adelaide, Australia

    Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
  • Abstract Number: 107 • 2019 ACR/ARP Annual Meeting

    Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium

    William Murray-Brown1, Yanxia Guo 2, Mihir Wechalekar 1, Helen Weedon 1, Malcolm Smith 1, Susanna Proudman 3, Navin Rao 4, Sunil Nagpal 4 and Mihir Wechalekar 1, 1Flinders University, Adelaide, Australia, 2Janssen Research, Spring House, 3Adelaide University, Adelaide, Australia, 4Janssen R&D, Spring House, PA

    Background/Purpose: Programmed cell death protein 1 (PD-1) expressing T-cells are implicated in the pathogenesis of autoimmune inflammatory diseases such as rheumatoid arthritis (RA). In secondary…
  • Abstract Number: 1182 • 2019 ACR/ARP Annual Meeting

    Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach

    Yogan Kisten1, Adrian Levitsky 1, Hamed Rezaei 1, Aase Hensvold 2, Per Larsson 3, Erik af Klint 1, Ronald van Vollenhoven 4 and Anca Catrina 5, 1Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 2Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, 3Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 4Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, 5Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: Among the arsenal of available techniques for arthritis prediction and diagnosis, fluorescence optical imaging (FOI) has shown to be useful in detecting clinically manifest…
  • Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting

    Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice

    isabel Hernandez Rodriguez1, Zulema Rosales Rosado 1, pia Lois 1, Cristina Lajas 1, Judit Font Urgelles 2, Juan Angel Jover Jover 1 and lydia Abasolo Alcazar 1, 1HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, 2HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain

    Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…
  • Abstract Number: 179 • 2019 ACR/ARP Annual Meeting

    The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry

    Sofia Pazmino 1, Veerle Stouten 1, Patrick Verschueren 2, Pavlos Mamouris 1, Rene Westhovens 3, Kurt De Vlam 2, Delphine Bertrand 1, Kristien Van der Elst 2, Bert Vaes 1 and Diederik De Cock1, 1KU Leuven, Leuven, Belgium, 2University Hospital Leuven, Leuven, Belgium, 3University Hospitals, Leuven, Belgium

    Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…
  • Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting

    Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)

    Orit Schieir1, Susan J. Bartlett 2, Marie-France Valois 3, Louis Bessette 4, Gilles Boire 5, Glen Hazlewood 6, Carol Hitchon 7, Edward Keystone 8, Janet Pope 9, Carter Thorne 10, Diane Tin 11, Vivian Bykerk 12 and Canadian Early Arthritis Cohort (CATCH) Investigators 13, 1University of Toronto, Montreal, Canada, 2McGill University, Montreal, QC, Canada, 3McGill University, Montreal, Canada, 4Laval University, Quebec City, QC, Canada, 5Sherbrooke University, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, Canada, 7University of Manitoba, Winnipeg, Canada, 8Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 9Western University, London, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Southlake Regional Health Centre, Newmarket, Canada, 12Hospital for Special Surgery, New York City, NY, 13Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…
  • Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting

    DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment

    Theodore Pincus1, jaquelin Chua 2, Joel Block 2 and Isabel Castrejon 2, 1Division of Rheumatology, Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, chicago, IL

    Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…
  • Abstract Number: 198 • 2019 ACR/ARP Annual Meeting

    Assessing Care Quality in Rheumatology Services

    Mark Yates1, Sam Norton 1, Alexander MacGregor 2, Katie Bechman 3, Sanketh Rampes 3 and James Galloway 4, 1Kings College London, London, 2University of East Anglia, Norwich, United Kingdom, 3King's College London, London, United Kingdom, 4Kings College London, London, United Kingdom

    Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
  • Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting

    Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

    Maria Powell1, Vivian Bykerk 2, Orit Schieir 3, Marie-France Valois 4, Susan J. Bartlett 5, Louis Bessette 6, Gilles Boire 7, Carol Hitchon 8, Edward Keystone 9, Janet Pope 10, Carter Thorne 11, Diane Tin 12 and Glen Hazlewood 1, 1University of Calgary, Calgary, AB, Canada, 2Hospital for Special Surgery, New York City, NY, 3University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 4McGill University, Montreal, Canada, 5McGill University, Montreal, QC, Canada, 6Laval University, Quebec City, QC, Canada, 7Sherbrooke University, Sherbrooke, QC, Canada, 8University of Manitoba, Winnipeg, Canada, 9Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 10Western University, London, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Southlake Regional Health Centre, Newmarket, Canada

    Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
  • Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting

    Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis

    Virginia Muir 1, Cliff Rims 1, Kevin Deane 2, Jeffrey Carlin 3, Sylvia Posso 1, Sunil Nagpal 4, Navin Rao 4, Frédéric Baribaud 5, George Vratsanos 6, William Robinson 7, Gary Firestein 8, V. Michael Holers 9, Peter Linsley 1, Eddie James1 and Jane Buckner 1, 1Benaroya Research Institute, Seattle, WA, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3Virginia Mason Medical Center, Seattle, WA, 4Janssen R&D, Spring House, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6JNJ, Raritan, NJ, 7Stanford University, Palo Alto, CA, 8University of California, San Diego, San Diego, 9University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
  • Abstract Number: 451 • 2019 ACR/ARP Annual Meeting

    Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores

    Vivian P. Bykerk1, Orit Schieir 2, Marie-France Valois 3, Gilles Boire 4, Glen Hazlewood 5, Louis Bessette 6, Carol Hitchon 7, Diane Tin 8, Carter Thorne 9, Edward Keystone 10, Janet Pope 11, Susan J. Bartlett 12 and Canadian Early Arthritis Cohort (CATCH) Investigators 13, 1Hospital for Special Surgery, New York, NY, 2University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 3McGill University, Montreal, Canada, 4Sherbrooke University, Sherbrooke, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6Laval University, Quebec City, QC, Canada, 7University of Manitoba, Winnipeg, Canada, 8Southlake Regional Health Centre, Newmarket, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 11Western University, London, ON, Canada, 12McGill University, Montreal, QC, Canada, 13Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada

    Background/Purpose: Persisting pain (NRS ≥4,) (PP) and non-articular pain (NAP), reduces quality of life for patients with RA. NAP is often attributed to fibromyalgia (FM),…
  • Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting

    Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

    Maxime Verhoeven1, Janneke Tekstra 1, Attila Pethö-Schramm 2, Michelle Borm 3, Jacob van Laar 1, Floris Lafeber 1, Johannes Bijlsma 1, Johannes Jacobs 1 and Paco Welsing 1, 1UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 2Hoffmann-La Roche, Basel, Basel, Switzerland, 3Roche Nederland BV, Woerden, Netherlands

    Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology